4//SEC Filing
Shah Jatin 4
Accession 0001209191-21-011494
CIK 0001503802other
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 6:48 PM ET
Size
9.5 KB
Accession
0001209191-21-011494
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2021-02-11$15.52/sh−1,748$27,127→ 48,127 total - Exercise/Conversion
Common Stock
2021-02-15+4,850→ 52,977 total - Exercise/Conversion
Restricted Stock Units
2021-02-15−4,850→ 9,700 total→ Common Stock (4,850 underlying)
Footnotes (4)
- [F1]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F2]The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
- [F3]Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- [F4]On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001782186
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 6:48 PM ET
- Size
- 9.5 KB